News archive
主2024
-
介质释放，介质释放 Novartis highlights pioneering innovation in CML with data from Scemblix ® Phase III ASC 4 FIRST study in newly diagnosed patients at ASCO and EHA Primary results of the Scemblix ® ASC4FIRST pivotal Phase III study in first-line Ph+CML-CP supporting third USFDA Breakthrough Therapy designation，to be detailed in the ASCO Press Program and the… -
Pulse Update Novartis receives FDA Breakthrough Therapy designation for Scemblix ® in1L CML -
介质释放，介质释放 Novartis enters agreement to acquire Mariana Oncology，strengthening radioligand therapy pipeline Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer Mariana Oncology is a preclinical-stage biotechnology company focused…
April2024
-
存储，存储 People and Culture From black holes to AI driven drug discovery–collaboration wins the day Dr Bülent K 栏的“字体”框中的字体）的可选字体名称 z 栏的“字体”框中的字体）的可选字体名称 人工和计算机科学技术 -
介质释放，介质释放 地下Venture announce positive efficicacy and safety data for annovel treatment for babies<5kg with malaria There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem ® （artemether-lumefantrine）to account for metabolic… -
介质释放，介质释放 Novartis radioligand therapy Lutathera ® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Approval based on NETTER-Ptrial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric（ages12-17）and adult patients Gastroenteropancreatic… -
Featured News Novartis Financial Results–Q12024 Novartis announced the company’s financial results for the first quarter of 2024。 -
关键帧Release Novartis delivers double-digit sales growth and core margin expansion in Q1； FY2024 guidance raised Ad hoc announcement pursuant to Art.53LQ1net sales grew+11%（cc1,+10%USD）with core operating income up+22%（cc，+16%USD）Key growth drivers continued strong sales momentum including… -
关键帧Release Novartis，au premier trimestre:croissanceàdeux chiffres du chiffre d′affaires et expansion de la marge core； hausse des prévisions pour 2024 Annonceévénementielle au sens de l’art。 53RCRésultats du premier trimestre（T1）Chifffre d’affaires net en hausse de+11%（tcc1,+10%USD）et durésultat opérationnel core，de+22%（tcc，+16%USD）… -
关键帧Release Novartis erzielt im ersten Quartal einzweistelliges Umsatzwachstum und steigert die Kerngewinnmarge； Prognose für das Geschäftsjahr2024erhöht Ad-hoc-Mitteilung gemäss Art.53KRDer Nettoumsatz wuchs im ersten Quartal um+11%（kWk1，+10%USD），das operative Kernergebnis verbesserte sichum+22%（kWk，+16%USD）Die wichtigsten… -
介质释放，介质释放 Novartis Kesimpta ® six-year efficicacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis Continuous Kesimpta ® treatment for up to six years showed sustained efficicacy in recently diagnosed（≤3 years）treatment-native people living with relapsing multiple sclerosis（RMS）in an analysis… -
介质释放，介质释放 新建Novartis Fabhalta ® （iptacopan）data show clinically meaningful and statistically significant proteinuria reduction of 38.3%versus placebo for patients with IgA nephropathy（IgAN） APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is aheterogeneous，progressive，rare…